CADE's Superintendence recommends approval of Cromossomo Participações-DASA deal with conditions
( May 9, 2014, 13:48 GMT | Official Statement) -- MLex Summary: The Brazilian competition authority’s lower unit, the Superintendence, has recommended the approval of plans by investor Cromossomo Participações to buy a stake in diagnostics company Diagnósticos da América provided they comply with commitments agreed by Cromossomo, which is part of Grupo Bueno. The Superintendence said that Grupo Bueno's commitments in a previous deal involving Dasa and MD1 are sufficient to address antitrust concerns. Grupo Bueno, which already had 23.59 percent of DASA, will now hold 70 percent of the company's capital. The case will now proceed to CADE's Tribunal for a final decision.Read the full statement below....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.